[Frontiers in Bioscience 12, 3468-3474, May 1, 2007]

Targeting the tumor microenvironment

Paraic A. Kenny, Genee Y. Lee and Mina J. Bissell

Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720

TABLE OF CONTENTS

1.Abstract
2. Introduction
3. Heterotypic cell signaling mediators
4. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5. Angiogenesis inhibitors
6. Aromatase inhibitors
7. Bisphosphonates
8. Conclusions
9. Acknowledgements
10. References

1. ABSTRACT

Despite some notable successes cancer remains, for the most part, a seemingly intractable problem. There is, however, a growing appreciation that targeting the tumor epithelium in isolation is not sufficient as there is an intricate mutually sustaining synergy between the tumor epithelial cells and their surrounding stroma. As the details of this dialogue emerge, new therapeutic targets have been proposed. The FDA has already approved drugs targeting microenvironmental components such as VEGF and aromatase and many more agents are in the pipeline. In this article, we describe some of the "druggable" targets and processes within the tumor microenvironment and review the approaches being taken to disrupt these interactions.